INMB INmune Bio
- 10.850
- -0.320-2.86%
- 10.850
- 0.0000.00%
INmune Bio News
Inmune Bio Inc Grants Stock Options to Top Executives
Analysts Offer Insights on Healthcare Companies: Inmune Bio (INMB), Insmed (INSM) and Tenet Healthcare (THC)
INmune Bio First Quarter 2024 Earnings: EPS Misses Expectations
Robust Pipeline and Financial Stability Underpin Buy Rating for Inmune Bio
INmune Bio | 10-Q: Quarterly report
INmune Bio Q1 2024 GAAP EPS $(0.61) Misses $(0.54) Estimate, Sales $14.000K Miss $30.000K Estimate
INmune Bio (NASDAQ:INMB) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.54) by 12.96 percent. This is a 69.44 percent decrease over losses of $(0.36)
Earnings Flash (INMB) INMUNE BIO Reports Q1 Revenue $14,000
04:21 PM EDT, 05/09/2024 (MT Newswires) -- Earnings Flash (INMB) INMUNE BIO Reports Q1 Revenue $14,000
Press Release: INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update
INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update Company to Host Conference Call Today, May 9, at 4:30pm ET BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- INmune
INmune Bio 1Q Loss/Shr 61c >INMB
INmune Bio 1Q Loss/Shr 61c >INMB
INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, May 07, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immun
INmune Bio Files for $250M Mixed Shelf Offering
Inmune Bio's Promising INKmune Therapy and Strong Financials Merit a Buy Rating
INmune Bio Inc. Provides Update on Two Patients From the Phase 1b Alzheimer's Disease Trial Who Continue to Receive XPro Under Compassionate Use for Over Three Years
Boca Raton, Florida, April 30, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology company focused on developing treatments that harness the patient
INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune Natural Killer Cell Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
Boca Raton, Florida, April 29, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology company focused on developing treatments that harness the patien
Insiders Of INmune Bio Are Up 38% On Their US$714.9k Purchase
INmune Bio, Inc. (NASDAQ:INMB) insiders who bought shares over the past year were rewarded handsomely last week. The stock rose 35%, resulting in a US$61m rise in the company's market capitalisation,
INmune Bio Says Remains On Track In Line With Prior Guidance To Complete Its Phase 2 Clinical Trial Involving The Use Of XPro For The Treatment Of Alzheimer's Disease In Patients With Biomarkers Of Neuroinflammation
INmune Bio Says Remains On Track In Line With Prior Guidance To Complete Its Phase 2 Clinical Trial Involving The Use Of XPro For The Treatment Of Alzheimer's Disease In Patients With Biomarkers Of Ne
Inmune Bio Earns Buy Rating on Positive XPro Developments and Strong Financials
INmune Bio Announces $9.7M Registered Direct Offering Of 986,000 Shares And Warrants At $9.84/Share And Accompanying Warrant
INmune Bio Announces $9.7M Registered Direct Offering Of 986,000 Shares And Warrants At $9.84/Share And Accompanying Warrant
(SEC Amendment) INmune Bio(INMB.US) 10% Shareholder Buys US$149.99K in Common Stock
$INmune Bio(INMB.US)$ 10% Shareholder Tesi Raymond Joseph purchased 18,028 shares of common stock on Apr 19, 2024 at an average price of $8.32 for a total value of $149.99K. This transaction involves
(SEC Amendment) INmune Bio(INMB.US) 10% Shareholder Buys US$120K in Common Stock
$INmune Bio(INMB.US)$ 10% Shareholder Lowdell Mark William purchased 14,423 shares of common stock on Apr 19, 2024 at an average price of $8.32 for a total value of $120K.Source: Announcement What is
Analysis
Price Target
No Data
